The traditional paradigm of cardiovascular disease research derives insight from large-scale, broadly inclusive clinical studies of well-characterized pathologies. These insights are then put into practice according to standardized clinical guidelines. However, stagnation in the development of new cardiovascular therapies and variability in therapeutic response implies that this paradigm is insufficient for reducing the cardiovascular disease burden. In this state-of-the-art review, we examine 3 interconnected ideas we put forth as key concepts for enabling a transition to precision cardiology: 1) precision characterization of cardiovascular disease with machine learning methods; 2) the application of network models of disease to embrace disease complexity; and 3) using insights from the previous 2 ideas to enable pharmacology and polypharmacology systems for more precise drug-to-patient matching and patient-disease stratification. We conclude by exploring the challenges of applying a precision approach to cardiology, which arise from a deficit of the required resources 
), the overall contribution of these loci to heritability in complex disease is often <10% (10). This "missing heritability" poses a significant problem for drug discovery: it implies that the strategy of targeting genetic regions discovered via GWAS, phenome-wide association studies, or loss-of-function studies will not provide clear-cut improvements for managing complex cardiovascular diseases moving forward (11, 12) . The productivity of drug discovery pipelines has declined despite accumulating demand for new therapies (13) (14) (15) . For example, highly targeted therapies such as the "-trapib" class of cholesterol esterase transfer protein inhibitors have repeatedly failed clinical trials (16) (17) (18) (19) .
In this state-of-the-art review, we identify 3 interconnected areas for new therapeutic opportunities in cardiovascular disease (20) . First, we discuss the incorporation of precision medicine concepts into cardiology, or precision cardiology. We use the term precision cardiology to mean more accurate and refined characterization and stratification of disease states and individual patient pathologies using multiple molecular and clinical features (21) This dichotomy provides a clear avenue to target treatments to an individual patient's mutational profile (26) (27) (28) (29) . The term is also used to define the application of genomic profiling and pharmacogenomics in a public health setting (30) (31) (32) (33) . Although genomic medicine (34, 35) utilizes genetic information, we envision going further by incorporating information from the transcriptome, proteome, and metabolome with longitudinal health care data, such as disease diagnoses, procedures, medications, and environmental exposure data (36) . We thus define precision cardiology as the application of multidimensional data to delineate subsets of the heterogeneous cardiovascular disease space. The ultimate aim of this approach is to enable patient stratification that can be used to better guide therapeutic interventions. However, tested hypotheses must be specified ahead of time, and these models do not easily fit data that may have underlying hidden structure (38) . Instead, the implementation of more advanced computational and informatics approaches is an integral requirement for precision cardiology. Specifically, machine learning techniques can be used to model and explore data in an unsupervised fashion (Central Illustration). 
ANALYZING CARDIOVASCULAR MULTISCALE

DATA WITH MACHINE LEARNING METHODS
In multi-omics studies, we do not know the exact mechanistic model that connects the different types of data. To address such uncertainties, statistical machine learning methods can be used to interrogate, model, and learn from complex multi-omics data.
The mathematical strategies underlying machine learning can be broadly defined as either supervised or unsupervised learning ( Table 1) . Supervised learning requires pre-defined labeling of the dataset (e.g., "cases" and "controls"). The labeled data is typically divided into training and testing datasets to Johnson et al.
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layers of hidden neurons (53-62 These algorithmic disease classification practices have an important role in building a foundation for more precise approaches. However, it is important to note that "E-phenotyping" approaches such as those by the eMERGE consortium are not a precision approach by themselves; instead, they generally propose to define the entire complexity of disease processes into simple "present" or "absent" disease classifications.
In contrast to the algorithmic "E-phenotyping" It is estimated that 44% of patients with essential hypertension were unable to achieve blood pressure control despite pharmacological therapy (72). 
EXAMPLES OF CARDIOVASCULAR DISEASES AMENABLE TO PRECISION SUBTYPING
Profiling patient populations using multi-omics approaches could help us to perform precision In the precision approach to cardiology, multi-omic information is incorporated to identify subtle strata of patients which can be differentially treated within the existing therapeutic space. ACE ¼ angiotensin-converting enzyme. Hospital's electronic health record data arranged around the central node. Distance from the central node is proportional to comorbidity odds ratio. We calculated comorbidity from ICD-9 codes using a logistic regression model controlling for age, sex, and self-reported ethnicity. Due to space limitations, we only show disease comorbidities with odds ratio $2. (Bottom) Networks of shared genetic architecture between CAD and HTN and other diseases, with shared genetic architecture defined as shared genome-wide association studies (GWAS) loci (gene level) between the 2 diseases. We compiled all data from GWASdb version 2 (August 2015) (159) and associated genes to a disease if they were GWAS threshold significant (p < 5 Â 10
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) and conferred an increased risk. We calculated shared genetic architecture using a and Hispanic/Latino. Using this network, we identified several interesting pairwise disease comorbidities that may not be captured using traditional epidemiological studies. For example, we 
DRUG REPOSITIONING AS AN AVENUE FOR DIRECTED INTERVENTIONS
Drug repositioning is a drug-discovery strategy that relies on a priori knowledge to recommend an existing drug for a new indication based on evidence from clinical data (e.g., off-label prescriptions) or biological experiments (e.g., gene expression profiling after drug perturbations) (111, 112) . Briefly, drug repositioning (Figure 4 ) relies on the concept that biological processes are mediated by a finite set of genes or gene-products and several biological entities (e.g., genes, proteins, and transcripts) have pleiotropic effects and mediate similar functions. We outline a detailed overview of drug repositioning and various repositioning strategies in our recent review exploring experimental and computational approaches in the drug repositioning space (20, 113) . We recently developed a reference database for drug repositioning investigations using primary Example of drugs originally developed or used for hypertension that have been repurposed for other indications. 
